As an aminoglycoside antibiotic effective for treating a wide variety of infections, Tobramycin CAS# 32986-56-4 is an integral medication that affects a vast number of patients. Tobramycin is particularly effectual for treating Gram-negative infections and certain Pseudomonas. The recent shortage of this crucial antibiotic has been felt for patients who take Tobramycin, either as an eye drop such as TobraDex or in its nebulized form like the brand name Tobi. Tobramycin is regularly used in its injectable form to treat serious central nervous system infections such as meningitis, septicemia, complicated urinary tract infections, and as an eye drop to treat bacterial infections of the eye. Side effects of Tobramycin are mild, and include nausea, diarrhea and stomach discomfort, as well as blurred vision and increased light sensitivity for patients who use the eye drop formula.
There is an inhaled formulation of Tobramycin that is especially efficacious for patients with Cystic Fibrosis. Statistics show that while not enough patients receive this life extending form of Tobramycin, the use of this formidable treatment for patients with CF is associated with a 21 percent reduction in the odds of next-year mortality. Furthermore, patients who regularly received Tobramycin to treat Pseudomonas aeruginosa experienced a 36 percent reduction in subsequent -year mortality. The Cystic Fibrosis Patient Foundation has been proactive in encouraging practitioners to treat patients with end stage CF more often with Tobramycin to provide them with improved lung function and greater life expectancy.
Whether you are seeking Tobramycin for compounding, or for research and development, LGM Pharma can meet your needs. LGM Pharma supplies Tobramycin API for R&D, as well as the Tobramycin TEVA API for compounding in the U.S.. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.